



Appl. No. : (U.S. National Phase Appln.

based on PCT/JP2003/011004)

Applicant : Tadashi NAKAJIMA et al

Filed : Concomitantly herewith

For : THERAPEUTIC AGENT FOR

GLAUCOMA COMPRISING Rho

KINASE INHIBITOR AND

PROSTAGLANDIN

Docket No. : 05116/HG

Customer No.: 01933

INFORMATION DISCLOSURE STATEMENT FILED CONCOMITANT WITH APPLICATION

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

Submitted herewith is a copy of the English language International Search Report (3 pages) issued in International Application No. PCT/JP2003/011004, on which the present U.S. national phase application is based.

Copies of the references cited in the International Search
Report have been supplied by WIPO to the USPTO. Therefore,
copies of the cited references in the International Search Report
should be on file in the United States, in accordance with
current U.S. practice.

Express Mail Mailing Label No.: EV 620 174 069 US Date of Deposit: February 25, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lori Valdes

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper to Account No. 06-1378.



Attached hereto is a Form PTO/SB/08A listing the particulars of the references cited in the International Search Report. As mentioned above, copies of the references should already be in the U.S. file, supplied by WIPO.

It is respectfully requested that the Examiner return an initialed copy of the attached Form PTO/SB/08A to confirm that the publications supplied by WIPO and listed therein have been considered and made of record.

Respectfully submitted,

HERBERT GOODMAN Reg. No. 17,081

Frishauf, Holtz, Goodman
& Chick, P.C.

767 Third Ave., 25th floor New York, NY 10017-2023 Telephone: (212) 319-4900 Facsimile: (212) 319-5101

HG/lpv

Enc: Form PTO/SB/08A; International Search Report

+						PTO/SB/08A (08-00)			
7.8.	Patent	and	Trademark	Office:	U.S.	DEPARTMENT	OF	COMMERCE	

Substi	tute	for F	orm 144	9A/	App	plica	tion Number	bas	National Phase Appln. Oased on PCT/JP2003/011004)					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT						Filing Date			10,525986 Concomitantly herewith					
						First Named Inventor			Tadashi NAKAJIMA et al					
						oup A	rt Unit							
					-					 				
					Exa	Examiner Name								
Sheet		1	of	1	Att	Attorney Docket Number			05116/HG					
	U.S. PATENT DOCUMENTS													
Exam. Inits*	Cite No ¹	Docum	ent Numbe	r		Kind Code ²	Name of Patentee of Applicant	or	Publication Date MM-DD-YYYY	Relevant Portion				
-									···					
							•		<u>.</u>					
FOREIGN PATENT DOCUMENTS														
Exam Inits	Cite No ¹	Offc Document Number4				Kind Code ⁵	Name of Patentee of Applicant	or	Publication Date MM-DD-YYYY	Relevant Portion	T ⁶			
/S.B./		EP	286903			A1	COLUMBIA UNIV.		10-19-1988					
/S.B./		wo	90/02553			A1	PHARMACIA AB		03-22-1990					
/S.B./		EP	308135 94/06433			A2	K.K. UENO SEIYAK	cu	03-22-1989					
/S.B./	•	wo				A1	ALLERGEN, INC.		03-31-1994					
/S.B./		EP	639563			A2 -	ALCON LAB. INC.		02-22-1995					
/S.B/		wo	0 00/09162			A1	SENJU PHARM. CO.		02-24-2000					
/S.B./	/S.B./		70 98/06433			A1	YOSHITOMI PHARM.		02-19-1998					
/S.B./		wo	0 97/23222			Al	ALCON LAB. INC. 07		07-03-1997					
Examin			/Sean B	asquill/			Date Considered		07/16/2008					

FEBRUARY 25, 2005 DATE MAILED:

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /S.B./

^{*} BXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Place a check here if English translation is attached.